Literature DB >> 30908864

Nanoparticle-Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions.

Jianping Liu1, Run Zhang1, Zhi Ping Xu1.   

Abstract

Cancer immunotherapy is a promising cancer terminator by directing the patient's own immune system in the fight against this challenging disorder. Despite the monumental therapeutic potential of several immunotherapy strategies in clinical applications, the efficacious responses of a wide range of immunotherapeutic agents are limited in virtue of their inadequate accumulation in the tumor tissue and fatal side effects. In the last decades, increasing evidences disclose that nanotechnology acts as an appealing solution to address these technical barriers via conferring rational physicochemical properties to nanomaterials. In this Review, an imperative emphasis will be drawn from the current understanding of the effect of a nanosystem's structure characteristics (e.g., size, shape, surface charge, elasticity) and its chemical modification on its transport and biodistribution behavior. Subsequently, rapid-moving advances of nanoparticle-based cancer immunotherapies are summarized from traditional vaccine strategies to recent novel approaches, including delivery of immunotherapeutics (such as whole cancer cell vaccines, immune checkpoint blockade, and immunogenic cell death) and engineered immune cells, to regulate tumor microenvironment and activate cellular immunity. The future prospects may involve in the rational combination of a few immunotherapies for more efficient cancer inhibition and elimination.
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cancer immunotherapy; engineered immune cells; multifunctional nanomaterials; specific delivery; tumor microenvironment

Year:  2019        PMID: 30908864     DOI: 10.1002/smll.201900262

Source DB:  PubMed          Journal:  Small        ISSN: 1613-6810            Impact factor:   13.281


  19 in total

1.  Promotion of CTL epitope presentation by a nanoparticle with environment-responsive stability and phagolysosomal escape capacity.

Authors:  Shuyun Dong; Sundharraman Subramanian; Kristin N Parent; Mingnan Chen
Journal:  J Control Release       Date:  2020-09-19       Impact factor: 9.776

2.  Active targeting of cancer cells by CD44 binding peptide-functionalized oil core-based nanocapsules.

Authors:  A De Capua; A Palladino; M Chino; C Attanasio; A Lombardi; R Vecchione; P A Netti
Journal:  RSC Adv       Date:  2021-07-13       Impact factor: 4.036

Review 3.  Nanoparticles Targeting STATs in Cancer Therapy.

Authors:  Milad Ashrafizadeh; Zahra Ahmadi; Niranjan G Kotla; Elham Ghasemipour Afshar; Saeed Samarghandian; Ali Mandegary; Abbas Pardakhty; Reza Mohammadinejad; Gautam Sethi
Journal:  Cells       Date:  2019-09-27       Impact factor: 6.600

Review 4.  Emerging nanomedicines for effective breast cancer immunotherapy.

Authors:  Amirhossein Bahreyni; Yasir Mohamud; Honglin Luo
Journal:  J Nanobiotechnology       Date:  2020-12-09       Impact factor: 10.435

Review 5.  Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy.

Authors:  Tianqi Wang; Yusuke Suita; Saradha Miriyala; Jordan Dean; Nikos Tapinos; Jie Shen
Journal:  Pharmaceutics       Date:  2021-04-09       Impact factor: 6.321

6.  Immunotherapy of Tumor RNA-Loaded Lipid Nanoparticles Against Hepatocellular Carcinoma.

Authors:  Yake Zhang; Fangyuan Xie; You Yin; Qin Zhang; Hong Jin; Yan Wu; Liying Pang; Jun Li; Jie Gao
Journal:  Int J Nanomedicine       Date:  2021-02-25

7.  Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy.

Authors:  Mingxia Jiang; Liping Zhao; Xiaoming Cui; Xinghan Wu; Yuhan Zhang; Xiuwen Guan; Jinlong Ma; Weifen Zhang
Journal:  J Adv Res       Date:  2021-08-19       Impact factor: 10.479

Review 8.  Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy.

Authors:  Ting Cai; Huina Liu; Shun Zhang; Jing Hu; Lingxiao Zhang
Journal:  J Nanobiotechnology       Date:  2021-11-25       Impact factor: 10.435

Review 9.  Drug delivery strategy in hepatocellular carcinoma therapy.

Authors:  Sisi Yang; Chengwei Cai; Huanqiu Wang; Xueqing Ma; Anwen Shao; Jifang Sheng; Chengbo Yu
Journal:  Cell Commun Signal       Date:  2022-03-05       Impact factor: 5.712

10.  Rapamycin-Loaded mPEG-PLGA Nanoparticles Ameliorate Hepatic Steatosis and Liver Injury in Non-alcoholic Fatty Liver Disease.

Authors:  Ruifang Zhao; Meilin Zhu; Shuang Zhou; Weiyue Feng; Hanqing Chen
Journal:  Front Chem       Date:  2020-05-28       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.